ficerafusp alfa (BCA101)

👍 BCA101 🙌 combined with Pembrolizumab video https://t.co/bj62xHP0HP shows positive results in treating metastatic Head and Neck cancer. @HeadNeckMD promising combo therapy brings hope for improved outcomes. #CancerResearch #BCA101 #Pembrolizumab #HeadAndNeckCancer #ASCO23 (@oncologytube)

Encouraging anti-tumor activity for patients w/metastatic head & neck squamous cell carcinoma who are HPV-negative and treated with bifunctional EGFR/TGFβ inhibitor BCA101 w/pembrolizumab. Dose expansion results reported by @DanaFarber's Glenn Hanna, MD, (@HeadNeckMD) at #ASCO23. (@DanaFarberNews)

Very promising activity observed with BCA101 + pembro in p16 negative cps 1-19% 1st line R/M HNSCC. Exceptional presentation by @HeadNeckMD at #ASCO23 (@AhernandoCalvo)

⁦@HeadNeckMD⁩ presenting BCA101 and pembrolizumab combination data in r/m hnscc. (@YilmazMDPhD)

📢 ASCO 2023 🎉 🔬 "BCA101 - The Potential of BCA101 in Cancer Treatment," sheds light on the cutting-edge research and innovative therapeutic strategies presented by 👨‍⚕️ Dr. @YilmazMDPhD at #ASCO23. @CleClinicMD #BCA101 #HeadandNeckCancer #ASCO23 📎 https://t.co/JkQq8a7T0V (@oncologytube)

Amazing work by BICARA team. Oral presentation @ASCO2023. BCA101 Pembrolizumab for metastatic HNSCC. New horizons. @HeadNeckMD @MoffittNews https://t.co/YsPtArgV30 (@JMuzaffarMD)

@HeadNeckMD at #ESMO22: BCA101, first-in-class bifunctional EGFR/TGFβ fusion protein, is well tolerated and clinically active +/- pembro in pts with advanced solid tumors. - 1/40 (2,5%) PR, 13/40 (33%) SD in BCA101 pts. - 4/13 (31%) PR, DCR of 9/13 (69%) in BCA101 +/- pembro pts. (@wearemedsir)

well this is interesting.. option for those w/ dual KRAS & HER2 mutations? Study of Safety & Tolerability of BCA101 Alone & in Combination W/ Pembrolizumab in Patients W/ EGFR-driven Advanced Solid Tumors 292 pts, Phase 1 PI: @FilipJankuMD @MDAndersonNews https://t.co/dP5IFyqPiO (@fireflyann)